Fig. 3

Relationship between risk model and efficacy of immunotherapy. A and B The survival curve showed the survival difference between the high-risk score and low-risk score groups in the immunotherapy imvigor210 cohort (A) and GSE78220 cohort (B). C In the imvigor210 cohort, there were differences in risk scores between different clinical responses to anti-PD-L1 treatment. D Differences in risk scores for different immunophenotypes in the imvigor210 cohort. E and F There were differences in risk scores between different neoantigen burdens (E) and mutation burden (F) in the imvigor210 cohort